Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Byoung Chul Cho | Researchclopedia

Back to researchers

Byoung Chul Cho

Hebron University ORCID

1,570

Works

69,558

Citations

106

h-index

476

i10-index

Research Topics

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies

Affiliations

Ulsan College2012–2017

Hebron University2020–2025

RCSI & UCD Malaysia Campus2011–2023

Universitat Autònoma de Barcelona2025–2025

University Health Network2011–2011

Top Works

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria,Yuichiro Ohe,et al.

20175,109 citations

Colorectal Cancer Treatments and Studies

Lung Cancer Diagnosis and Treatment

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia,Augusto Villegas,et al.

20174,435 citations

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok,Yi‐Long Wu,et al.

20193,277 citations

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia,Augusto Villegas,et al.

20182,753 citations

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam,Johan Vansteenkiste,et al.

20192,714 citations

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele,Alexander Drilon,et al.

20191,695 citations

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress,Cloud P. Paweletz,et al.

20151,519 citations

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun,Lin Shen,et al.

20211,515 citations

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato,Byoung Chul Cho,et al.

20191,206 citations